Skip to main content

Find Clinical Trials

Home
Conditions
Lung Neoplasms

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

4,205 public trials 1,002 recruiting studies

Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Active, Not Recruiting

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

NCT04379739

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Shanghai Pulmonary Hospital Shang'ai, Shanghai Municipality, China

View Trial Details

Active, Not Recruiting

Quest for Tumour Evolution of Non-small Cell Lung Cancer

NCT05811169

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Department of Clinical Oncology, Queen Mary Hospital Hong Kong

View Trial Details

Active, Not Recruiting

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

NCT03836352

Conditions: Adenocarcinoma, Adnexal Diseases, Bladder Cancer, +39 more
Locations: The University of Arizona Cancer Center Tucson, Arizona, United States

Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center Los Angeles, California, United States

Boca Raton Regional Hospital, Lynn Cancer Institute Boca Raton, Florida, United States

Hematology Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States

View all 23 locations

View Trial Details

Active, Not Recruiting

Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer

NCT04304248

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Sun Yat sen University cancer center Guangzhou, Guangdong, China

View Trial Details

Active, Not Recruiting

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

NCT02493582

Conditions: Adenocarcinoma, Adenocarcinoma of Lung, Carcinoma, +7 more
Locations: Not specified

View Trial Details